Specialty Pharma Journal Specialty, Precision & Technology
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …
Read More »FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Recent Posts
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq: INCY) today announced that data from the Novartis pivotal Phase 2 …
Read More »Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded
SAN CARLOS, Calif., Sept. 2, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and …
Read More »Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion
BRISBANE, Calif.–(BUSINESS WIRE)–Aug. 31, 2020– Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments …
Read More »Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (Nasdaq: TWST) today announced data demonstrating the potent …
Read More »Final Analysis of the Observational GioTag Study: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive NSCLC
Ingelheim, Germany, 2nd September 2020 – Boehringer Ingelheim today announced the final analysis from GioTag, a …
Read More »Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
Pratteln, Switzerland, and Rockville, MD, USA, September 2, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it …
Read More »FDA Approves Onureg, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration …
Read More »FDA Accepts Vertex’s sNDA for Trikafta, Symdeko and Kalydeco for Additional CFTR Mutations
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted …
Read More »Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement …
Read More »FDA Accepts and Grants Priority Review to Athenex’s NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer
BUFFALO, N.Y., Sept. 01, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical …
Read More »Sanofi provides update on Kevzara Phase 3 trial in severe and critically ill COVID-19 patients outside the US
PARIS – September 1, 2020 – Sanofi today announced that the global Phase 3 trial investigating intravenously …
Read More »Roche Receives FDA Approval for First HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the Fight Against HIV/AIDS
Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food …
Read More »Boston Pharmaceuticals Licenses Non-Alcoholic Steatohepatitis Development Candidate from Novartis
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Boston Pharmaceuticals today announced an agreement with Novartis through which Boston Pharmaceuticals will license …
Read More »Development of COVID-19 Vaccine AZD1222 Expands Into US Phase 3 Clinical Trial Across All Adult Age Groups
WILMINGTON, Del.–(BUSINESS WIRE)–AZD1222 development expanded into a Phase III clinical trial in the US to …
Read More »